Related Experiment Video
Updated: Jan 19, 2026
Cooperative Binding of Transcription Regulators
Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes
Julian Musa1, Florencia Cidre-Aranaz1, Marie-Ming Aynaud2
1Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Abstract:
Pediatric malignancies including Ewing sarcoma (EwS) feature a paucity of somatic alterations except for pathognomonic driver-mutations that cannot explain overt variations in clinical outcome. Here, we demonstrate in EwS how cooperation of dominant oncogenes and regulatory germline variants determine tumor growth, patient survival and drug response. Binding of the oncogenic EWSR1-FLI1 fusion transcription factor to a polymorphic enhancer-like DNA element controls expression of the transcription factor MYBL2 mediating these phenotypes. Whole-genome and RNA sequencing reveals that variability at this locus is inherited via the germline and is associated with variable inter-tumoral MYBL2 expression. High MYBL2 levels sensitize EwS cells for inhibition of its upstream activating kinase CDK2 in vitro and in vivo, suggesting MYBL2 as a putative biomarker for anti-CDK2-therapy. Collectively, we establish cooperation of somatic mutations and regulatory germline variants as a major determinant of tumor progression and highlight the importance of integrating the regulatory genome in precision medicine.
Insights
In Ewing sarcoma (EwS), inherited genetic variations and oncogenes cooperate to influence tumor growth and drug response. High MYBL2 expression indicates sensitivity to CDK2 inhibitors, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Ewing sarcoma (EwS) shows limited somatic alterations, yet clinical outcomes vary significantly.
- The role of germline variants in pediatric malignancies like EwS is not fully understood.
Purpose of the Study:
- To investigate how oncogenes and germline variants cooperate to drive EwS progression and affect treatment response.
- To identify potential biomarkers for targeted therapies in EwS.
Main Methods:
- Whole-genome and RNA sequencing were employed to analyze tumor samples.
- The study focused on the interaction between EWSR1-FLI1, a polymorphic enhancer, and MYBL2 expression.
Main Results:
- A polymorphic enhancer element, regulated by EWSR1-FLI1, controls MYBL2 expression.
- Germline variations at this locus correlate with MYBL2 expression levels.
- Elevated MYBL2 sensitizes EwS cells to CDK2 inhibition, both in vitro and in vivo.
Conclusions:
- Cooperation between somatic mutations and germline variants significantly impacts EwS tumor progression.
- MYBL2 serves as a potential biomarker for anti-CDK2 therapy in EwS.
- Integrating the regulatory genome is crucial for advancing precision medicine in pediatric cancers.
Related Concept Videos
Cooperative Binding of Transcription Regulators
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
06:52Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Cis-regulatory Sequences
11:29miRNA Expression Analyses in Prostate Cancer Clinical Tissues
